The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010

Drug and Alcohol Dependence

Volumn 137, Issue 1, 2014, Pages 36-47

  Degenhardt, Louisa ^a,b   Baxter, Amanda J ^c,d   Lee, Yong Yi ^c,d   Hall, Wayne ^e,f   Sara, Grant E ^d,g,h   Johns, Nicole ⁱ   Flaxman, Abraham ⁱ   Whiteford, Harvey A ^c,d   Vos, Theo ⁱ  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Queensland Centre for Mental Health Research   (Australia)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g New South Wales Government   (Australia)

^h UNIVERSITY OF SYDNEY   (Australia)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Amphetamines; Burden of disease; Cocaine; Epidemiology; Psychostimulants

Indexed keywords

AMPHETAMINE DEPENDENCE; ARTICLE; ASIA; BAYES THEOREM; COCAINE DEPENDENCE; COMORBIDITY; DISABILITY; DISABILITY ADJUSTED LIFE YEAR; DRUG DEPENDENCE; GEOGRAPHIC DISTRIBUTION; HUMAN; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REGISTER; REMISSION; STATISTICAL MODEL; WESTERN HEMISPHERE; ADULT; COST OF ILLNESS; ECONOMICS; FEMALE; HEALTH; MALE; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

CENTRAL STIMULANT AGENT;

ADULT; BAYES THEOREM; CENTRAL NERVOUS SYSTEM STIMULANTS; COST OF ILLNESS; FEMALE; GLOBAL HEALTH; HUMANS; MALE; REGISTRIES; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84896086708     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2013.12.025     Document Type: Article

References (70)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, Washington, DC. fourth ed.
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC. fourth ed. - technical revision.
3. Baker A., Lee N., Jenner L. Models of Intervention and Care for Psychostimulant Users. National Drug Strategy Monograph Series No. 51 2004, Australian Government Department of Health and Ageing, Canberra. second ed.
4. Calabria B., Degenhardt L., Briegleb C., Vos T., Hall W., Lynskey M., Callaghan B., Rana U., McLaren J. Systematic reviews of prospective studies investigating remission from amphetamine, cannabis, cocaine and opioid dependence. Addict. Behav. 2010, 35:741-749.
5. Castells X., Casas M., PerezMana C., Roncero C., Vidal X., Capella D. Efficacy of psychostimulant drugs for cocaine dependence (review). Cochrane Rev. 2010, 2. Art.No.: CD007380. 10.1002/14651858.CD007380.pub3.
6. Conner K.R., Pinquart M., Holbrook A.P. Meta-analysis of depression and substance use and impairment among cocaine users. Drug Alcohol Depend 2008, 98:13-23.
7. Cornish J.W., O'Brien C.P. Crack cocaine abuse: an epidemic with many public health consequences. Annu. Rev. Public Health 1996, 17. 2559-2273.
8. Cregler L.L. Adverse health consequences of cociane abuse. J. Natl. Med. Assoc. 1989, 81:27-38.
9. Curran C., Byrappa N., McBride A. Stimulant psychosis: systematic review. Br. J. Psychiatry 2004, 185:196-204.
10. Darke S., Kaye S. Attempted suicide among injecting and noninjecting cocaine users in Sydney, Australia. J. Urban Health 2004, 81:505-515.
11. Degenhardt L., Bruno R., Topp L. Is ecstasy a drug of dependence?. Drug Alcohol Depend 2010, 107:1-10.
12. Degenhardt L., Bucello C., Calabria B., Nelson P., Roberts A., Hall W., Lynskey M., LWiessing L. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend. 2011, 117:85-101. for the GBD Illicit Drug Use Writing Group.
13. Degenhardt L., Calabria B., Nelson P., Bucello C., Roberts A., Thomas J., Hall W. What Do We Know About the Extent of Amphetamine Use and Dependence? Results of a Global Systematic Review. NDARC Technical Report 2010, National Drug and Alcohol Research Centre, University of NSW, Sydney.
14. Degenhardt L., Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012, 379:55-70.
15. Degenhardt L., Mathers B., Vickerman P., Rhodes T., Latkin C., Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet 2010, 376:285-301.
16. Degenhardt L., Mathers B., Wirtz A., Wolfe D., Carrieri P., Strathdee S., Kamarulzaman A., Malinowska-Sempruch K., Sidibe M., Beyrer C. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012?. A review of the six highest burden countries. Int. J. Drug Policy 2014, 25:53-60.
17. Degenhardt L., Roxburgh A., Black E., Bruno R., Campbell G., Kinner S., Fetherston J. The epidemiology of methamphetamine use and harm in Australia. Drug Alcohol Rev. 2008, 27(3):243-252.
18. Degenhardt L., Singleton J., Calabria B., McLaren J., Kerr T., Mehta S., Kirk G., Hall W. Mortality among cocaine users: a systematic review of cohort studies. Drug Alcohol Depend 2011, 113:88-95.
19. Degenhardt L., Whiteford H., Ferrari A.J., Baxter A., Charlson F., Hall W., Freedman G., Burstein R., Johns N., Engell R.E., Flaxman A.D., Murray C., Vos T. The global burden of disease attributable to illicit drug use and dependence: results from the GBD 2010 study. Lancet 2013, 382:1564-1574.
20. Degenhardt L., Whiteford H., Hall W. The global burden of disease projects: What have we learned about illicit drug use and dependence and their contribution to global burden of disease? (Invited commentary). Drug Alcohol Rev. 2014, 33(1):4-12.
21. Degenhardt L., Day C., Hall W., Conroy E., Gilmour S. Was an increase in cocaine use among injecting drug users in New South Wales, Australia, accompanied by an increase in violent crime?. BMC Public Health 2005, 5.
22. Falck R.S., Wang J., Siegal H.A., Carlson R.G. Current physical health problems and their predictors among a community sample of crack-cocaine smokers in Ohio. J. Psychoactive Drugs 2003, 35:471-478.
23. Ferrari A., Norman R., Freedman G., Baxter A.J., Pirkis J., Harris M., Page A., Carnaham E., Degenhardt L., Vos L., Whiteford H. The burden attributable to mental and substance use disorders as independent risk factors for suicide: findings from the Global Burden of Disease Study 2010. PLoS One 2014, (in press).
24. General Department for Social Evils Prevention, Constella Group, Department of International Development (DFID) Economic and Public Health Analysis of Institutional and Community Responses to Injecting Drug Use and HIV/AIDS in Vietnam: Draft report of the findings from Data Collection and Cost Analysis in Four Rehabilitation Centres 2008, Duc Hanh (HCMC), Ba Ria-Vung Tau, Khanh Hoa and Tay Ninh, Hanoi.
25. Grant B.F., Moore T., Kaplan K. Source and Accuracy Statement: Wave 1 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) 2003, Retrieved from http://niaaa.census.gov (02.07.03).
26. Haasen C., Prinzleve M., Gossop M., Fischer G., Casas M. Relationship between cocaine use and mental health problems in a sample of European cocaine powder or crack users. World Psychiatry 2005, 4:173-176. the Cocaine EU-Team.
27. Hermens D.F., Lubman D.I., Ward P.B., Naismith S.L., Hickie I.B. Amphetamine psychosis: a model for studying the onset and course of psychosis. Med. J. Aust. 2009, 190(4 Suppl.):S22-S25.
28. Human Rights Watch Not Enough Graves: The War on Drugs, HIV/AIDS, and Violations of Human Rights 2004, Human Rights Watch, New York.
29. Jürgens R., Csete J., Amon J.J., Baral S., Beyrer C. People who use drugs, HIV, and human rights. The Lancet 2010, 376(9739):475-485.
30. Kaye S., Darke S. Injecting and non-injecting cocaine use in Sydney, Australia: physical and psychological morbidity. Drug Alcohol Rev. 2004, 23:391-398.
31. Knapp W.P., Soares B.G., Farrell M., Lima M.S. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders (review). Cochrane Rev. 2007, 8. Art. No.: CD003023. 10.1002/14651858.CD003023.pub2.
32. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991, 14:299-302.
33. Lim S.S., Vos T., Flaxman A.D., Danaei G., Shibuya K., Adair-Rohani H., Amann M., Anderson K.G., Andrews M., Aryee C., Atkinson L.J., Bacchus A.N., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2224-2260.
34. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., Abraham J., Adair T., Aggarwal R., Ahn S.Y., Alvarado M., Anderson H.R., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
35. Marzuk P.M., Tardiff K., Leon A.C., Stajic M., Morgan E.B., Mann J.J. Prevalence of cocaine use among residents of New York City who committed suicide during a one-year period. Am. J. Psychiatry 1992, 149:371-375.
36. Mathers B., Degenhardt M., Phillips L., Wiessing B., Hickman L., Strathdee M., Wodak S.A., Panda A., Tyndall S., Toufik M., Mattick A., for the 2007 Reference Group to the UN on HIV and Injecting Drug Use Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008, 371:1733-1745.
37. Ministerial Council on Drug Strategy National Amphetamine Type Stimulant Strategy 2008-2011 2008, Australian Government, Canberra.
38. Moher D., Liberati A., Tetzlaff J., Altman D.G., The Prisma Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. PLoS Med. 2009, 6:e1000097.
39. Mooney M., Sofuoglu M., Dudish-Poulsen S., Hatsukami D.K. Preliminary observations of paranoia in a human laboratory study of cocaine. Addict. Behav. 2006, 31:1245-1254.
40. Murray C.J., Lopez A.D. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020 1996, Harvard University Press, Boston, MA.
41. Murray C.J.L., Vos T., Lozano R., Naghavi M., Flaxman A.D., Michaud C., Ezzati M., Shibuya K., Salomon J.A., Abdalla S., Aboyans V., Abraham J., et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2197-2223.
42. Open Society Institute International Harm Reduction Development Program Public Health Fact Sheet. Human Rights Abuses in the Name of Drug Treatment: Reports From the Field 2009, Open Society Institute, New York.
43. Pearshouse R. Compulsory Drug Treatment in Thailand: Observations on the Narcotic Addict Rehabilitation Act B.E. 2545 2009, 2002. Canadian HIV/AIDS Legal Network, Toronto.
44. Prince M., Patel V., Saxena S., Maj M., Maselko J., Phillips M., Rahman A. No health without mental health. Lancet 2007, 370:859-877.
45. Ribeiro M., Dunn J., Sesso R., Dias A.C., Laranjeira R. Causes of death among crack cocaine users. Rev. Brasil. Psiq. 2006, 28:196-202.
46. Roy A. Characteristics of cocaine-dependent patients who attempt suicide. Am. J. Psychiatry 2001, 158:1215-1219.
47. Salomon J.A., Vos T., Hogan D.R., Gagnon M., Naghavi M., Mokdad A., Begum N., Shah R., Karyana M., Kosen S., Farje M.R., Moncada G., et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380:2129-2143.
48. Satel S.L., Southwick S.M., Gawin F.H. Clinical features of cocaine-induced paranoia. Am. J. Psychiatry 1991, 148:495-498.
49. Singleton J., Degenhardt L., Hall W., Zabransky T. Mortality among people who use amphetamines: a systematic review of cohort studies. Drug Alcohol Depend 2009, 105:1-8.
50. Srisurapanont M., Jarusuraisin N., Kittirattanapaiboon P. Treatment for amphetamine dependence and abuse (review). Cochrane Rev. 2001, Art. No.: CD003022. 10.1002/14651858.CD003022.
51. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., TSipe T.A., Thacker S.B., for the Meta-analysis Of Obervational Studies in Epidemiology (MOOSE) Group Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000, 283:2008-2012.
52. Topp L., Darke S. The applicability of the dependence syndrome to amphetamine. Drug Alcohol Depend. 1997, 48:113-118.
53. Topp L., Mattick R.P. Validation of the amphetamine dependence syndrome and the SamDQ. Addiction 1997, 92:157-167.
54. Topp L., Mattick R.P. Choosing a cut-off on the Severity of Dependence Scale (SDS) for amphetamine users. Addiction 1997, 92:839-845.
55. UNODC World Drug Report 2006 2007, United Nations, Vienna.
56. UNODC 2008 Global ATS Assessment: Amphetamines and Ecstasy 2008, United Nations, Vienna.
57. UNODC World Drug Report 2008 2008, United Nations, Vienna.
58. UNODC World Drug Report 2009 2009, United Nations, Vienna.
59. UNODC World Drug Report 2011 2011, United Nations Publication, Vienna.
60. UNODC World Drug Report 2012 2012, United Nations, Vienna.
61. UNODC World Drug Report 2013 2013, Vienna, United Nations.
62. UNODC Regional Centre for East Asia and the Pacific HIV/AIDS and custodial settings in South East Asia - An exploratory review into the issues of HIV/AIDS and custodial settings in Cambodia, China, Lao PDR, Myanmar, Thailand and Viet Nam 2006, UNODC, Thailand, Bangkok.
63. Vos T., Flaxman A.D., Naghavi M., Lozano R., Michaud C., Ezzati M., Shibuya K., Salomon J.A., Abdalla S., Aboyans V., Abraham J., Ackerman I., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380(9859):2163-2196.
64. Wang H., Dwyer-Lindgren L., Lofgren K.T., Rajaratnam J.K., Marcus J.R., Levin-Rector A., Levitz C.E., Lopez A.D., Murray C.J.L. Age-specific and sex-specific mortality in 187 countries, 1970-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2071-2094.
65. World Bank World Development Report 1993: Investing in Health 1993, University Press, Oxford, New York.
66. World Health Organization The ICD-10 Classification of Mental and Behavioural Disorders - Diagnostic Criteria for Research 1993, World Health Organization, Geneva.
67. World Health Organization Neuroscience of Psychoactive Substance Use and Dependence 2004, World Health Organization, Geneva.
68. World Health Organization The Global Burden of Disease: 2004 Update 2008, World Health Organization, Geneva.
69. World Health Organization Assessment of Compulsory Treatment of People Who Use Drugs in Cambodia, China, Malaysia and Viet Nam: An Application of Selected Human Rights Principles 2009, World Health Organization, Manila.
70. World Health Organization/United Nations lnterregional Crime and Justice Research Institute Cocaine Project 1995, World Health Organization, Geneva.